244 related articles for article (PubMed ID: 18399960)
1. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
Zhu W; Xie W; Pan T; Jankovic J; Li J; Youdim MB; Le W
J Neurochem; 2008 Jun; 105(5):1970-8. PubMed ID: 18399960
[TBL] [Abstract][Full Text] [Related]
2. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W
FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
5. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
6. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection by rasagiline in thiamine deficient rats.
Eliash S; Dror V; Cohen S; Rehavi M
Brain Res; 2009 Feb; 1256():138-48. PubMed ID: 19103184
[TBL] [Abstract][Full Text] [Related]
8. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement.
Pan T; Kondo S; Zhu W; Xie W; Jankovic J; Le W
Neurobiol Dis; 2008 Oct; 32(1):16-25. PubMed ID: 18640276
[TBL] [Abstract][Full Text] [Related]
11. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Li C; Biswas S; Li X; Dutta AK; Le W
J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
17. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.
Sagi Y; Mandel S; Amit T; Youdim MB
Neurobiol Dis; 2007 Jan; 25(1):35-44. PubMed ID: 17055733
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
